| (a) | by inserting, immediately after paragraph (g) of item (23) of paragraph 1, the following paragraph:| “(h) | 1-Cyclopropionyl-N,N-diethyllysergamide (also known as 1-Cyclopropionyl-LSD or 1cP-LSD)”; |
|
|
| (b) | by deleting item (36) of paragraph 1; |
| (c) | by inserting, immediately after item (14A) of paragraph 15, the following item:| “(14B) | 1-(4-Fluoro-3-methylphenyl)-2-(pyrrolidin-1-yl)pentan-1-one (also known as 4-Fluoro-3-methyl-α-pyrrolidinopentiophenone or 4-Fluoro-3-methyl-α-PVP)”; |
|
|
| (d) | by inserting, immediately after item (6E) of paragraph 17, the following items:| “(6F) | 4-Bromo-N-[2-(dimethylamino)cyclohexyl]-benzamide (also known as Bromadoline or U‑47931E) and its bromo positional isomers in the phenyl ring and diamino positional isomers in the cyclohexyl ring | | (6G) | 4-Bromo-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzamide (also known as N-Methyl U‑47931E or N‑Methyl Bromadoline) and its bromo positional isomers in the phenyl ring and diamino positional isomers in the cyclohexyl ring”; |
|
|
| (e) | by inserting, immediately after item (10) of paragraph 17, the following item:| “(10AAA) | 3,4-Dibromo-N-methyl-N-(1-methyl-1-azaspiro[4.5]decan-6-yl)benzamide (also known as U-77891) and its dibromo positional isomers in the phenyl ring and their respective azaspiro[4.5]decanyl isomers”; |
|
|
| (f) | by inserting, immediately after item (10B) of paragraph 17, the following item:| “(10C) | N,N-Diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzo[d]imidazol-1-yl)ethan-1-amine (also known as Isotonitazene) and its diethylamino structural isomers and their respective isopropoxy positional isomers in the phenyl ring and nitro positional isomers in the 6‑membered ring of the benzimidazole structure”; |
|
|
| (g) | by inserting, immediately after item (18) of paragraph 17, the following item:| “(18A) | 1-(1,2-Diphenylethyl)piperidine (also known as Diphenidine)”; |
|
|
| (h) | by inserting, immediately after item (19) of paragraph 17, the following item:| “(19A) | 2-(Ethylamino)-2-phenyl-cyclohexan-1-one (also known as Deschloro-N-ethyl-ketamine)”; |
|
|
| (i) | by inserting, immediately after item (20AB) of paragraph 17, the following item:| “(20B) | 2-(3-Fluorophenyl)-3-methylmorpholine (also known as 3‑Fluorophenmetrazine or 3F‑phenmetrazine) and its fluoro positional isomers in the phenyl ring”; |
|
|
| (j) | by inserting, immediately after item (27) of paragraph 17, the following item:| “(27AA) | 5-(5-Hydroxypentyl)-2-(2-phenylpropan-2-yl)-pyrido[4,3-b]indol-1-one and its phenylpropyl isomers and their respective hydroxy positional isomers in the pentyl group”; |
|
|
| (k) | by inserting, immediately after item (28) of paragraph 17, the following items:| “(28A) | 1-[1-(2-Methoxyphenyl)-2-phenylethyl]piperidine (also known as 2-MeO-Diphenidine or 2-MXP or methoxphenidine) and its methoxy positional isomers in the phenyl ring | | (28B) | N-Methyl-5-(2-aminopropyl)benzofuran (also known as 5‑MAPB) and its 4‑yl, 6‑yl and 7‑yl isomers”; |
|
|
| (l) | by inserting, immediately after item (36) of paragraph 17, the following item:| “(37) | 2-Phenyl-2-(methylamino)cyclohexanone (also known as Deschloroketamine)”; |
|
|
| (m) | by inserting, immediately after item (38AC) of paragraph 17, the following item:| “(38B) | 5-[(2-Phenylpropan-2-yl)-pyrido[4,3-b]indol-1-one-yl]pentanoic acid and its phenylpropyl isomers”; |
|
|
| (n) | by inserting, immediately after item (39) of paragraph 17, the following item:| “(40) | 2,4,5-Trimethoxy-α-methylphenethylamine (also known as 2,4,5-Trimethoxyamphetamine or TMA-2) and its trimethoxy positional isomers in the phenyl ring”; |
|
|
| (o) | by inserting, immediately after item (5) of paragraph 20, the following item:| “(5A) | N-(1-Adamantyl)-1-(4-fluorobutyl)-1H-indazole-3-carboxamide (also known as 4-Fluoro-ABUTINACA or 4F-ABUTINACA or 4-Fluoro ABINACA)”; |
|
|
| (p) | by inserting, immediately after item (7) of paragraph 20, the following item:| “(7A) | N-(1-Adamantyl)-4-hydroxybutyl-1H-indazole-3-carboxamide”; |
|
|
| (q) | by inserting, immediately after item (15) of paragraph 20, the following item:| “(15A) | 4-{3-[(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)carbamoyl]-1H-indazole-1-yl}butanoic acid”; |
|
|
| (r) | by inserting, immediately after item (31) of paragraph 20, the following item:| “(31A) | 2-[1-(4-Fluorobutyl)-1H-indole-3-carboxamido]-3,3-dimethylbutanoic acid”; |
|
|
| (s) | by inserting, immediately after item (36) of paragraph 20, the following items:| “(36A) | 2-[1-(5-Fluoropentyl)-1H-indole-3-carboxamido]-3-phenylpropanoic acid | | (36B) | 1-(5-Hydroxypentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide”; |
|
|
| (t) | by inserting, immediately after item (51) of paragraph 20, the following item:| “(51A) | Methyl 2-[1-(5-hydroxypentyl)-1H-indole-3-carboxamido]-3-phenylpropanoate”; and |
|
|
| (u) | by deleting item (59) of paragraph 20 and substituting the following item:| “(59) | 4-{3-[(2-Phenylpropan-2-yl)carbamoyl]-1H-indazole-1-yl}butanoic acid”. |
|
|
